Marshall Wace’s C4 Therapeutics CCCC Stock Holding History

Marshall Wace’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Buy	227,003 +71,508	+46%	+$245K	﹤0.01%	2161
2026 Q1	$409K	Sell	155,495 -109,532	-41%	-$258K	﹤0.01%	2536
2025 Q4	$506K	Buy	265,027 +158,752	+149%	+$376K	﹤0.01%	2231
2025 Q3	$236K	Buy	+106,275	New	+$255K	﹤0.01%	2523
2025 Q1	–	Sell	-36,167	Closed	-$130K	–	2657
2024 Q4	$130K	Sell	36,167 -189,249	-84%	-$941K	﹤0.01%	2419
2024 Q3	$1.28M	Buy	+225,416	New	+$1.36M	﹤0.01%	1544
2024 Q2	–	Sell	-146,644	Closed	-$1.2M	–	2578
2024 Q1	$1.2M	Sell	146,644 -976,417	-87%	-$7.57M	﹤0.01%	1580
2023 Q4	$6.35M	Buy	+1,123,061	New	+$2.56M	0.01%	827
2023 Q2	–	Sell	-113,236	Closed	-$356K	–	2507
2023 Q1	$356K	Buy	+113,236	New	+$667K	﹤0.01%	2240
2022 Q3	–	Sell	-252,326	Closed	-$1.9M	–	3376
2022 Q2	$1.9M	Buy	+252,326	New	+$2.22M	﹤0.01%	2036

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace's CCCC Position: Q2 2026 in Review

Marshall Wace increased its C4 Therapeutics (CCCC) stake by 46% in Q2 2026, buying an estimated $245K and bringing the position to 227,003 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

Marshall Wace first reported a position in CCCC in Q2 2022 and has held it in 10 quarters since. The position peaked at $6.35M in Q4 2023. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Marshall Wace held 227,003 shares of C4 Therapeutics worth $1.06M as of Q2 2026.
Marshall Wace bought 71,508 C4 Therapeutics shares in Q2 2026, an estimated $245K.
C4 Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2161 holding.
Marshall Wace first reported a position in C4 Therapeutics in Q2 2022 and has held it in 10 quarters since.
Marshall Wace's C4 Therapeutics position peaked at $6.35M in Q4 2023.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.